NBO Pharma Inc.
About NBO Pharma Inc.
NBO Pharma Inc. was incorporated in 2021 to develop a drug for the treatment of Idiopathic Intracranial Hypertension (IIH), a condition with no approved drugs. The company is repurposing the existing orphan drug octreotide acetate in an intranasal formulation, which is undergoing clinical trials for IIH. It operates as a privately held biotechnology research company focused on pharmaceuticals. Headquarters are in Bedford, New York.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $7.6M in Seed round via Form D filed January 2026 with 93 investors.
- Developing intranasal octreotide for Idiopathic Intracranial Hypertension with no approved treatments.
- Incorporated in Delaware in 2021 as a privately held operating company.
- Maintains low web traffic of 274 monthly visits and no open roles listed.
Ask StreetZero about NBO Pharma Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account